Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Clinical activity and molecular response (GORTEC 2008-02)

导出原文传递

翻译打印收藏纠错

作者： Schmitz,S. ^[1] ; Kaminsky-Forrett,M.-C. ^[2] ; Henry,S. ^[3] ; Zanetta,S. ^[4] ; Geoffrois,L. ^[5] ; Bompas,E. ^[6] ; Moxhon,A. ^[7] ; Mignion,L. ; Guigay,J. ; Knoops,L. ; Hamoir,M. ; Machiels,J.-P.

作者单位： Department of Medical Oncology, Center Alexis Vautrin, Nancy, France ^[1] Department of Medical Oncology, Center G-F Leclerc, Dijon, France ^[2] Cancer Center, University Hospital St-Luc, Catholic University Louvain, Brussels, Belgium ^[3] Department of Medical Oncology, Catholic University Louvain, Mont-Godinne and St-Elisabeth, Namur ^[4] Department of Medical Oncology, Gustave Roussy Institut, Villejuif, France ^[5] Department of Medical Oncology, Center René Gauducheau, Nantes, France ^[6] Cancer Center, University Hospital St-Luc, Catholic University Louvain, Brussels, Belgium, Ludwig ^[7]

关键词 Figitumumab Head and neck cancer Insulin-like growth factor receptor Phase II study Targeted therapy

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交